Tamtam Try Tamtam free
Straumann Group logo

Straumann Group account plan

Dental innovations and achievements

At a glance

Straumann Group is a Basel-based dental implant, orthodontics and digital dentistry company with 2025 revenue of CHF 2.6 billion and about 12 000 employees.

Straumann Group, headquartered in Basel, Switzerland, develops, manufactures and sells dental implants, prosthetics, clear aligners, biomaterials and digital equipment under brands including Straumann, Neodent, Medentika, Anthogyr and ClearCorrect. It sells to dentists, dental labs and dental service organizations (DSOs) in more than 100 countries from 18 production sites. FY2025 revenue was CHF 2 605.4 million (+8.9% organic), with core EBIT of CHF 655.5 million (25.2% margin) and IFRS net profit of CHF 358.0 million. Year-end 2025 headcount was 11 824. The company is listed in Switzerland, with a market capitalization of CHF 14 903 million at end-2025.

Business units

Strategic priorities

Expand implant leadership
Grow share in a CHF 6.1 billion implant market where Straumann holds above 35%, led by iEXCEL (close to 40% of premium implant volumes in H1 2026) and challenger brand Neodent.
Digital ecosystem around scanners
Use intraoral scanners as the gateway to the Straumann AXS cloud platform, which has more than 20 000 active users; AXS users show substantially higher reorder rates.
Transform orthodontics
Refocus ClearCorrect on general practitioners and DSOs, with production moved to the Smartee platform and break-even targeted by the end of 2027.
Win DSOs
A tiered coverage model and consultative selling for DSOs; roughly 20% of implants are placed by DSO-affiliated practitioners, expected to reach as much as 30% in major markets by 2029.
Margin expansion to 2030
Around 10% average annual revenue growth over the mid term and 40 to 50 basis points of annual core EBIT margin increase at constant currency until 2030, supported by the "Unlocking value" initiative.

Latest results

Q3 2026 revenue was CHF 667.1 million, up 9.2% organically and 10.8% in Swiss francs, bringing nine-month revenue to CHF 2 046.5 million (+8.3% organic). In H1 2026, revenue was CHF 1 379.5 million (+7.8% organic) with a core EBIT margin of 25.7% (26.9% at constant 2025 rates) and free cash flow of CHF 169 million. All regions contributed, with EMEA and APAC growing double-digit in Q3, while Latin America moderated. The 2026 outlook was confirmed in October: high single-digit organic revenue growth and core EBIT margin expansion of around 140 to 170 basis points at constant 2025 exchange rates.

Investments and deals

Manufacturing capacity
Over CHF 1 billion went into manufacturing capacity over four years; 2025 capex was CHF 223.5 million, mainly in Shanghai, Curitiba, Calw and Villeret, and implant capacity doubles by 2026.
Third Neodent factory
The third Neodent factory in Curitiba, Brazil, opened in September 2026.
Villeret center of excellence
CHF 60 to 80 million committed over five years to make Villeret a center of excellence for precision manufacturing and automation.
Acquisitions in ceramics and AI
maxon dental GmbH went to full ownership in June 2025 and became Straumann Ceramic; full ownership of Promaton (AI for dental applications) followed in 2025.
Headquarters move
The headquarters is planned to move to Arlesheim, Switzerland.

Challenges and risks

China volume-based procurement
China saw a double-digit decline from Q3 2025 ahead of VBP 2.0, whose implementation is anticipated in Q1 2027.
Tariffs and currency
Tariffs cost around CHF 20 million in 2025 COGS, and FX is expected to have an 80 to 100 bps negative impact on the 2026 EBIT margin.
Soft consumer demand
North America faces cautious consumer sentiment, and Brazilian patient flow through large dental groups lost momentum in Q3 2026.
Orthodontics losses
ClearCorrect is not yet profitable, with break-even targeted for the end of 2027 and a German plant closure in the transition.
Leadership transition and litigation
CEO Guillaume Daniellot leaves at the end of 2026, succeeded by Christopher Norbye, and H1 2026 carried CHF 18.0 million of legal costs from the Align Technology litigation.

What leadership says

“Continued share gains for iEXCEL reinforce our leadership in premium implantology, while Neodent keeps on expanding access to treatment in more markets”

Guillaume Daniellot, CEO · Q3 2026 results release, 28 October 2026.

“Every digital workflow in our ecosystem starts with a scan.”

Guillaume Daniellot, CEO · Half-year 2026 results call, 19 August 2026.

“In today's dental market, product performance alone is no longer sufficient.”

Guillaume Daniellot, CEO · Full-year 2025 results call, 18 February 2026.

“at least two-thirds of the improvement we have seen is structural”

Isabelle Wege, CFO · On margin gains, half-year 2026 results call, 19 August 2026.

Where a supplier can help

Precision manufacturing and automation
The Villeret center of excellence, the new Curitiba factory and doubled implant capacity call for machining, automation and quality equipment.
Digital and AI platform partners
Scaling Straumann AXS and AI case assessment opens room for cloud, data and software partners tied to the digital ecosystem priority.
Supply chain and tariff mitigation
Tariff costs and the shift to local-for-local production create needs for trade, logistics and supply chain tools.
Efficiency programmes
The "Unlocking value" initiative (procurement, operations excellence, working capital) and disciplined OpEx favour suppliers that cut cost.
DSO selling and CRM
The DSO priority and consultative selling model can use sales enablement, CRM and education tooling.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Straumann Group?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Straumann Group

What does Straumann Group do?

Straumann develops, manufactures and sells dental implants, prosthetics, clear aligners, biomaterials and digital dentistry equipment such as intraoral scanners, under brands including Straumann, Neodent and ClearCorrect.

What is Straumann Group's revenue?

FY2025 revenue was CHF 2 605.4 million, up 8.9% organically; nine-month 2026 revenue was CHF 2 046.5 million.

How many employees does Straumann Group have?

Headcount was 11 824 at end-2025 and 11 582 at the end of June 2026.

What is Straumann Group's strategy?

Under "Go Beyond" it aims to expand implant leadership, win DSOs, transform orthodontics and grow its digital ecosystem, targeting around 10% annual revenue growth over the mid term.

Who leads Straumann Group?

Guillaume Daniellot is CEO until the end of 2026, when Christopher Norbye succeeds him; Isabelle Wege is CFO and Petra Rumpf chairs the Board.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)